AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Arcturus revenue collapsed 90% YoY to $3.0M as CSL collaboration wound down; company terminated vaccine partnership on August 3, 2026, regaining strategic control but facing $5.2M deferred revenue recognition and future royalty obligations.
Biggest Revenue Drivers
Grant revenue$2.079M-45% YoY
BARDA reimbursement declined due to program phase transition; Gates Foundation grants increased.
Collaboration revenue$0.880M-96% YoY
CSL Seqirus revenue collapsed as KOSTAIVE transitioned from development to commercial phase with reduced supply agreement revenue.
Biggest Revenue Drivers
Total revenue: $2.959M-90% YoY
Grant revenue$2.079M-45% YoY
BARDA reimbursement declined due to program phase transition; Gates Foundation grants increased.
Collaboration revenue$0.880M-96% YoY
CSL Seqirus revenue collapsed as KOSTAIVE transitioned from development to commercial phase with reduced supply agreement revenue.
Largest Expense Items
Research and development, net$17.515M-41% YoY
Lower clinical trial expenses for BARDA, LUNAR-CF, and LUNAR-OTC programs; reduced manufacturing costs and headcount reductions including lower share-based compensation.
General and administrative$10.989M+6% YoY
Slight increase driven by legal and professional fees, partially offset by reduced share-based compensation.
Margins: Gross margin not disclosed; operating loss widened to $25.5M from $11.6M YoY despite 41% reduction in R&D spending, reflecting revenue collapse that outpaced expense cuts. Company expects $5.2M deferred revenue recognition in Q3 2026 from CSL termination settlement.
Watch Items from the Filing
CSL Seqirus accounted for $0.874M (96% of Q2 collaboration revenue), down from $24.4M YoY. Termination effective August 3, 2026 eliminates this revenue stream but provides $12M cash payment and $16M liability release; company obligated to pay future single-digit royalties on vaccine commercialization.
Cash and equivalents declined to $191.5M from $230.9M at year-end 2025; company burning ~$39M cash per half-year. Management states current cash 'will be sufficient to meet anticipated cash requirements through at least the next twelve months' but acknowledges need for additional financing if development accelerates.
LUNAR-CF/ARCT-032 Phase 2 trial advanced with fourth cohort (up to 20 subjects) enrolling at 10 mg daily via inhalation over 12 weeks; prior cohorts showed safety and tolerability with no bronchospasm reported. Thermo Fisher agreement provides up to $40M clinical manufacturing services with exclusive commercial manufacturing rights post-approval.
LUNAR-OTC/ARCT-810 Phase 2 enrollment completed; all subjects finished dosing. Company evaluating supplementary data and preparing for End-of-Phase 2 meeting with FDA regarding regulatory pathway, though trial results not yet disclosed.
Company in litigation with AbbVie Inc. and Capstan Therapeutics over trade secret misappropriation and breach of contract (filed September 2025); Capstan asserted counterclaims for trade secret misappropriation. No quantified exposure disclosed; trial date not yet set.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Kurata LanceChief Legal OfficerGrant or award · Dec 17, 2025
Payne Joseph EPresident and CEOGrant or award · Dec 17, 2025
About Arcturus Therapeutics Holdings Inc. (ARCT): stock profile, AI score and financials
Arcturus Therapeutics Holdings Inc. (ARCT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARCT at 7.5/100 on a composite quality score built from its SEC filings, placing it at rank #2,902 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.4) and profitability (4.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Arcturus Therapeutics Holdings Inc. reports quarterly revenue of $3.0M, net income of $-23.8M, free cash flow of $-19.9M. Top institutional holders of ARCT by reported 13-F value include FEDERATED HERMES, ARK Investment Management, BlackRock, based on the most recent SEC filings. ARCT trades on the Nasdaq exchange and files with the SEC under CIK 1768224. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arcturus Therapeutics Holdings Inc. directly from SEC EDGAR.